Trabectedin for Recurrent Grade II/III Meningioma

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

January 16, 2019

Conditions
Recurrent High Grade Meningioma
Interventions
DRUG

Trabectedin

Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.

OTHER

Local standard of care

Left to the discretion of the investigator

Trial Locations (47)

33075

CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre, Bordeaux

69120

Universitaetsklinikum Heidelberg - UniversitaetsKlinikum Heidelberg - Head Hospital, Heidelberg

79106

Universitaetsklinikum Freiburg - Klinik fuer Neurochirurgie, Freiburg im Breisgau

81377

Ludwig-Maximilians-Universitaet Muenchen - Klinikum der Universitaet Muenchen - Campus Grosshadern, München

Unknown

Landesnervenklinik Wagner Jauregg, Linz

Medical University Vienna - General Hospital AKH, Vienna

Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Brussels

Universitair Ziekenhuis Antwerpen, Edegem

Universitair Ziekenhuis Gent, Ghent

U.Z. Leuven - Campus Gasthuisberg, Leuven

CHU Dinant Godinne - UCL Namur, Yvoir

CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer, Bron

Centre Georges-Francois-Leclerc, Dijon

CHRU de Lille, Lille

Centre Leon Berard, Lyon

Institut régional du Cancer Montpellier, Montpellier

CHU de Nice - Hopital Pasteur, Nice

Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere, Paris

Centre Eugene Marquis, Rennes

Gustave Roussy, Villejuif

Universitaetsklinikum Bonn, Bonn

Universitaetsklinikum - Essen, Essen

Klinikum Der J.W. Goethe Universitaet, Frankfurt

Universitaetsklinikum Leipzig, Leipzig

Universitaetsklinikum Muenster, Zentralklinikum, Münster

Universitaetskliniken Regensburg, Regensburg

Eberhard Karls Universitaet Tuebingen - Universitaetsklinikum Tuebingen, Tübingen

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan

Ospedale San Raffaele, Milan

Istituto Oncologico Veneto IRCCS - Ospedale Busonera, Padua

Istituto Regina Elena / Istituti Fisioterapici Ospitalieri, Roma

Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale San Giovanni - Dipartimento Neuroscienze, Torino

Spaarne Gasthuis - Vrije Universiteit Medisch Centrum, Amsterdam

University Medical Center Groningen, Groningen

Erasmus MC Cancer Institute - location Daniel den Hoed, Rotterdam

Oslo University Hospital - Radiumhospitalet, Oslo

Hospital Clinic Universitari de Barcelona, Barcelona

Hospital De La Santa Creu I Sant Pau, Barcelona

Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Barcelona

Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia), L'Hospitalet de Llobregat

Hospital Universitario 12 De Octubre, Madrid

Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne

UniversitaetsSpital Zurich, Zurich

University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre, Bristol

NHS Lothian - Western General Hospital, Edinburgh

Guy's and St Thomas' NHS - St Thomas Hospital, London

Newcastle Hospitals NHS Trust - Freeman Hospital, Northern Centre For Cancer Care, Newcastle

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT02234050 - Trabectedin for Recurrent Grade II/III Meningioma | Biotech Hunter | Biotech Hunter